Efficacy and Safety of Deucravacitinib for Psoriasis: A Multicenter Real-World Analysis Focusing on Scalp Outcomes—IL PSO (Italian Landscape Psoriasis) - Takeaways - MDSpire

Efficacy and Safety of Deucravacitinib for Psoriasis: A Multicenter Real-World Analysis Focusing on Scalp Outcomes—IL PSO (Italian Landscape Psoriasis)

  • By

  • Luciano Ibba

  • Sara Di Giulio

  • Piergiorgio Malagoli

  • Anna Balato

  • Angelo Valerio Marzano

  • Matteo Megna

  • Diego Orsini

  • Lidia Sacchelli

  • Santo Raffaele Mercuri

  • Emanuele Trovato

  • Serena Giacalone

  • Alexia Pedron

  • Marzia Caproni

  • Edoardo Cammarata

  • Aldo Cuccia

  • Andrea Altomare

  • Alexandra M. G. Brunasso

  • Valentina Dini

  • Simone Ribero

  • Nicola Zerbinati

  • Francesco Messina

  • Stefano Caccavale

  • Carlo G. Carrera

  • Luca Potestio

  • Viviana Lora

  • Andrea Carugno

  • Federico Bardazzi

  • Giovanni Paolino

  • Antonio Costanzo

  • Alessandra Narcisi

  • Mario Valenti

  • March 16, 2026

  • 0 min

Share

  • 1

    Deucravacitinib is an oral TYK2 inhibitor approved for moderate-to-severe psoriasis, particularly effective for scalp involvement.

  • 2

    A multicenter study involving 111 patients showed promising short-term results after 16 weeks of treatment with deucravacitinib.

  • 3

    Patients experienced rapid and sustained effectiveness on scalp psoriasis, with further improvement noted at 32 weeks.

  • 4

    The study highlights the need for real-world evidence to assess the effectiveness and safety of treatments for difficult-to-treat psoriasis areas.

  • 5

    Deucravacitinib's favorable safety profile and efficacy support its use in patients with inadequate responses to conventional therapies.

Original Source(s)

Efficacy and Safety of Deucravacitinib for Psoriasis: A Multicenter Real-World Analysis Focusing on Scalp Outcomes—IL PSO (Italian Landscape Psoriasis)

  • by Luciano Ibba, Sara Di Giulio, Piergiorgio Malagoli, Anna Balato, Angelo Valerio Marzano, Matteo Megna, Diego Orsini, Lidia Sacchelli, Santo Raffaele Mercuri, Emanuele Trovato, Serena Giacalone, Alexia Pedron, Marzia Caproni, Edoardo Cammarata, Aldo Cuccia, Andrea Altomare, Alexandra M. G. Brunasso, Valentina Dini, Simone Ribero, Nicola Zerbinati, Francesco Messina, Stefano Caccavale, Carlo G. Carrera, Luca Potestio, Viviana Lora, Andrea Carugno, Federico Bardazzi, Giovanni Paolino, Antonio Costanzo, Alessandra Narcisi, Mario Valenti

  • March 16, 2026

Related Content

Bimekizumab in Psoriasis: 3-Year Outcomes

Investigators compare patient-reported symptoms and quality-of-life outcomes vs secukinumab.

Dermatologic outcomes associated with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a large-scale target trial emulation

Understanding the Perspectives and Experiences of Canadian Psoriasis Patients with Diverse Skin Tones